Refine
Year of publication
Document Type
- Article (36)
- Doctoral Thesis (3)
Has Fulltext
- yes (39)
Is part of the Bibliography
- no (39) (remove)
Keywords
- apoptosis (39) (remove)
Institute
- Medizin (39) (remove)
In eukaryotes, double-stranded (ds) RNA induces sequence-specific inhibition of gene expression referred to as RNA interference (RNAi). We exploited RNAi to define the role of HER2/neu in the neoplastic proliferation of human breast cancer cells. We transfected SK-BR-3, BT-474, MCF-7, and MDA-MB-468 breast cancer cells with short interfering RNA (siRNA) targeted against human HER2/neu and analyzed the specific inhibition of HER2/neu expression by Northern and Western blots. Transfection with HER2/neu-specific siRNA resulted in a sequence-specific decrease in HER2/neu mRNA and protein levels. Moreover, transfection with HER2/neu siRNA caused cell cycle arrest at G0/G1 in the breast cancer cell lines SKBR-3 and BT-474, consistent with a powerful RNA silencing effect. siRNA treatment resulted in an antiproliferative and apoptotic response in cells overexpressing HER2/neu, but had no influence in cells with almost no expression of HER2/neu proteins like MDA-MB-468 cells. These data indicate that HER2/neu function is essential for the proliferation of HER2/neuoverexpressing breast cancer cells. Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as anti proliferative agents that display activity against neoplastic cells at very low doses.
Photodynamic treatment of oral squamous cell carcinoma cells with low curcumin concentrations
(2017)
Objective: Curcumin is known for its anti-oxidative, anti-inflammatory and anti-tumorigenic qualities at concentrations ranging from 3.7µg/ml to 55µg/ml. Therefore it is pre-destined for tumour therapy. Due to high oral doses that have to be administered and the low bioavailability of curcumin new therapy concepts have to be developed. One of these therapy concepts is the combination of low curcumin concentrations and UVA or visible light. Aim of our study was to investigate the influence of this treatment regime on oral squamous cell carcinoma cells.
Materials and Methods: A human oral squamous cell carcinoma cell line (HN) was pre-incubated with low curcumin concentrations (0.01µg/ml to 1µg/ml). Thereafter cell cultures were either left un-irradiated or were irradiated either with 1J/cm2 UVA or for 5min with visible light. Quantitative analysis of proliferation, membrane integrity, oxidative potential and DNA fragmentation were done.
Results: It could be shown that low curcumin concentrations neither influenced proliferation, nor cell morphology, nor cell integrity nor apoptosis. When combining these curcumin concentrations with UVA or visible light irradiation cell proliferation as well as development of reactive oxygen species was reduced whereas DNA fragmentation was increased. Concentration as well as light entity specific effects could be observed.
Conclusions: The present findings substantiate the potential of the combination of low curcumin concentrations and light as a new therapeutic concept to increase the efficacy of curcumin in the treatment of cancer of the oral mucosa.
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis
(2015)
High polo-like kinase 1 (PLK1) expression has been linked to poor outcome in neuroblastoma (NB), indicating that it represents a relevant therapeutic target in this malignancy. Here, we identify a synergistic induction of apoptosis by the PLK1 inhibitor BI 2536 and vinca alkaloids in NB cells. Synergistic drug interaction of BI 2536 together with vincristine (VCR), vinblastine (VBL) or vinorelbine (VNR) is confirmed by calculation of combination index (CI). Also, BI 2536 and VCR act in concert to reduce long-term clonogenic survival. Importantly, BI 2536 significantly enhances the antitumor activity of VCR in an in vivo model of NB. Mechanistically, BI 2536/VCR co-treatment triggers prolonged mitotic arrest, which is necessary for BI 2536/VCR-mediated apoptosis, since pharmacological inhibition of mitotic arrest by the CDK1 inhibitor RO-3306 significantly reduces cell death. Prolonged mitotic arrest leads to phosphorylation-mediated inactivation of BCL-2 and BCL-XL as well as downregulation of MCL-1, since inhibition of mitotic arrest by RO-3306 also prevents phosphorylation of BCL-2 and BCL-XL and MCL-1 downregulation. This inactivation of antiapoptotic BCL-2 proteins promotes activation of BAX and BAK, cleavage of caspase-9 and -3 and caspase-dependent apoptosis. Engagement of the mitochondrial pathway of apoptosis is critically required for BI 2536/VCR-induced apoptosis, since ectopic expression of a non-degradable MCL-1 phospho-mutant, BCL-2 overexpression or BAK knockdown significantly reduce BI 2536/VCR-mediated apoptosis. Thus, PLK1 inhibitors may open new perspectives for chemosensitization of NB.
Recently, the conserved intracellular digestion mechanism ‘autophagy’ has been considered to be involved in early tumorigenesis and its blockade proposed as an alternative treatment approach. However, there is an ongoing debate about whether blocking autophagy has positive or negative effects in tumor cells. Since there is only poor data about the clinico-pathological relevance of autophagy in gliomas in vivo, we first established a cell culture based platform for the in vivo detection of the autophago-lysosomal components. We then investigated key autophagosomal (LC3B, p62, BAG3, Beclin1) and lysosomal (CTSB, LAMP2) molecules in 350 gliomas using immunohistochemistry, immunofluorescence, immunoblotting and qPCR. Autophagy was induced pharmacologically or by altering oxygen and nutrient levels. Our results show that autophagy is enhanced in astrocytomas as compared to normal CNS tissue, but largely independent from the WHO grade and patient survival. A strong upregulation of LC3B, p62, LAMP2 and CTSB was detected in perinecrotic areas in glioblastomas suggesting micro-environmental changes as a driver of autophagy induction in gliomas. Furthermore, glucose restriction induced autophagy in a concentration-dependent manner while hypoxia or amino acid starvation had considerably lesser effects. Apoptosis and autophagy were separately induced in glioma cells both in vitro and in vivo. In conclusion, our findings indicate that autophagy in gliomas is rather driven by micro-environmental changes than by primary glioma-intrinsic features thus challenging the concept of exploitation of the autophago-lysosomal network (ALN) as a treatment approach in gliomas.
Smac mimetics antagonize IAP proteins, which are highly expressed in several cancers. Recent reports indicate that Smac mimetics trigger a broad cytokine response and synergize with immune modulators to induce cell death. Here, we identify a differential requirement of TRAIL or TNFα as mediators of IFNα/Smac mimetic-induced cell death depending on the cellular context. Subtoxic concentrations of Smac mimetics cooperate with IFNα to induce cell death in various solid tumor cell lines in a highly synergistic manner as determined by combination index. Mechanistic studies show that IFNα/BV6 cotreatment promotes the formation of a caspase-8-activating complex together with the adaptor protein FADD and RIP1. Assembly of this RIP1/FADD/caspase-8 complex represents a critical event, since RIP1 silencing inhibits IFNα/BV6-induced cell death. Strikingly, pharmacological inhibition of paracrine/autocrine TNFα signaling by the TNFα scavenger Enbrel rescues HT-29 colon carcinoma cells, but not A172 glioblastoma cells from IFNα/BV6-induced cell death. By comparison, A172 cells are significantly protected against IFNα/BV6 treatment by blockage of TRAIL signaling through genetic silencing of TRAIL or its cognate receptor TRAIL receptor 2 (DR5). Despite this differential requirement of TNFα and TRAIL signaling, mRNA and protein expression is increased by IFNα/BV6 cotreatment in both cell lines. Interestingly, A172 cells turn out to be resistant to exogenously added recombinant TNFα even in the presence of BV6, whereas they display a high sensitivity towards TRAIL/BV6. In contrast, BV6 efficiently sensitizes HT-29 cells to TNFα while TRAIL only had limited efficacy. This demonstrates that a differential sensitivity towards TRAIL or TNFα determines the dependency on either death receptor ligand for IFNα/Smac mimetic-induced cell death. Thus, by concomitant stimulation of both death receptor systems IFNα/Smac mimetic combination treatment is an effective strategy to induce cell death in TNFα- or TRAIL-responsive cancers.
We previously reported that aberrant HH pathway activation confers a poor prognosis in rhabdomyosarcoma (RMS). Searching for new treatment strategies we therefore targeted HH signaling. Here, we identify a novel synthetic lethality of concomitant inhibition of HH and PI3K/AKT/mTOR pathways in RMS by GLI1/2 inhibitor GANT61 and PI3K/mTOR inhibitor PI103. Synergistic drug interaction is confirmed by calculation of combination index (CI < 0.2). Similarly, genetic silencing of GLI1/2 significantly increases PI103-induced apoptosis. GANT61 and PI103 also synergize to induce apoptosis in cultured primary RMS cells emphasizing the clinical relevance of this combination. Importantly, GANT61/PI103 cotreatment suppresses clonogenic survival, three-dimensional sphere formation and tumor growth in an in vivo model of RMS. Mechanistic studies reveal that GANT61 and PI103 cooperate to trigger caspase-dependent apoptosis via the mitochondrial pathway, as demonstrated by several lines of evidence. First, GANT61/PI103 cotreatment increases mRNA and protein expression of NOXA and BMF, which is required for apoptosis, since knockdown of NOXA or BMF significantly reduces GANT61/PI103-induced apoptosis. Second, GANT61/PI103 cotreatment triggers BAK/BAX activation, which contributes to GANT61/PI103-mediated apoptosis, since knockdown of BAK provides protection. Third, ectopic expression of BCL-2 or non-degradable phospho-mutant MCL-1 significantly rescue GANT61/PI103-triggered apoptosis. Fourth, GANT61/PI103 cotreatment initiate activation of the caspase cascade via apoptosome-mediated cleavage of the initiator caspase-9, as indicated by changes in the cleavage pattern of caspases (e.g. accumulation of the caspase-9 p35 cleavage fragment) upon addition of the caspase inhibitor zVAD.fmk. Thus, combined GLI1/2 and PI3K/mTOR inhibition represents a promising novel approach for synergistic apoptosis induction and tumor growth reduction with implications for new treatment strategies in RMS.
The deregulation of Polo-like kinase 1 is inversely linked to the prognosis of patients with diverse human tumors. Targeting Polo-like kinase 1 has been widely considered as one of the most promising strategies for molecular anticancer therapy. While the preclinical results are encouraging, the clinical outcomes are rather less inspiring by showing limited anticancer activity. It is thus of importance to identify molecules and mechanisms responsible for the sensitivity of Polo-like kinase 1 inhibition. We have recently shown that p21Cip1/CDKN1A is involved in the regulation of mitosis and its loss prolongs the mitotic duration accompanied by defects in chromosome segregation and cytokinesis in various tumor cells. In the present study, we demonstrate that p21 affects the efficacy of Polo-like kinase 1 inhibitors, especially Poloxin, a specific inhibitor of the unique Polo-box domain. Intriguingly, upon treatment with Polo-like kinase 1 inhibitors, p21 is increased in the cytoplasm, associated with anti-apoptosis, DNA repair and cell survival. By contrast, deficiency of p21 renders tumor cells more susceptible to Polo-like kinase 1 inhibition by showing a pronounced mitotic arrest, DNA damage and apoptosis. Furthermore, long-term treatment with Plk1 inhibitors induced fiercely the senescent state of tumor cells with functional p21. We suggest that the p21 status may be a useful biomarker for predicting the efficacy of Plk1 inhibition.
Linear Ubiquitin chain Assembly Complex (LUBAC) is an E3 ligase complex that generates linear ubiquitin chains and is important for tumour necrosis factor (TNF) signaling activation. Mice lacking Sharpin, a critical subunit of LUBAC, spontaneously develop inflammatory lesions in the skin and other organs. Here we show that TNF receptor 1 (TNFR1)-associated death domain (TRADD)-dependent TNFR1 signaling in epidermal keratinocytes drives skin inflammation in Sharpin-deficient mice. Epidermis-restricted ablation of Fas-associated protein with death domain (FADD) combined with receptor-interacting protein kinase 3 (RIPK3) deficiency fully prevented skin inflammation, while single RIPK3 deficiency only delayed and partly ameliorated lesion development in Sharpin-deficient mice, showing that inflammation is primarily driven by TRADD- and FADD-dependent keratinocyte apoptosis while necroptosis plays a minor role. At the cellular level, Sharpin deficiency sensitized primary murine keratinocytes, human keratinocytes, and mouse embryonic fibroblasts to TNF-induced apoptosis. Depletion of FADD or TRADD in Sharpin-deficient HaCaT cells suppressed TNF-induced apoptosis, indicating the importance of FADD and TRADD in Sharpin-dependent anti-apoptosis signaling in keratinocytes.
Evasion of apoptosis, for example, by inhibitor of apoptosis (IAP) proteins, contributes to treatment resistance and poor outcome in acute myeloid leukemia (AML). Here we identify a novel synergistic interaction between the small-molecule second mitochondria-derived activator of caspases (Smac) mimetic BV6, which antagonizes X-linked IAP, cellular IAP (cIAP)1 and cIAP2, and the demethylating agents 5-azacytidine or 5-aza-2′-deoxycytidine (DAC) to induce cell death in AML cells, including apoptosis-resistant cells. Calculation of combination index (CI) confirms that this drug combination is highly synergistic (CI 0.02–0.4). In contrast, BV6 and DAC at equimolar concentrations do not cause synergistic toxicity against normal peripheral blood lymphocytes, pointing to some tumor cell selectivity. Molecular studies reveal that BV6 and DAC cooperate to trigger the activation of caspases, mitochondrial perturbations and DNA fragmentation, consistent with apoptotic cell death. However, the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) fails to protect against BV6/DAC-induced cell death and even significantly increases the percentage of Annexin-V/propidium iodide double-positive cells. Importantly, BV6/DAC-induced cell death in the presence of zVAD.fmk is significantly reduced by pharmacological inhibition of key components of necroptosis signaling, that is, receptor-interacting protein (RIP) 1 using necrostatin-1 or mixed lineage kinase domain-like protein (MLKL) using necrosulfonamide. This indicates a switch from BV6/DAC-induced cell death from apoptosis to necroptosis upon caspase inhibition. Thus, BV6 cooperates with demethylating agents to induce cell death in AML cells and circumvents apoptosis resistance via a switch to necroptosis as an alternative mode of cell death. The identification of a novel synergism of BV6 and demethylating agents has important implications for the development of new treatment strategies for AML.
Apoptosis represents one of the most important forms of cell death in higher organisms and is typically dysregulated in human cancers, including pediatric tumors. This implies that ineffective engagement of cell death programs can contribute to tumor formation as well as tumor progression. In addition, the majority of cytotoxic therapeutic principles rely on the activation of cell death signaling pathways in cancer cells. Blockade of signaling networks that lead to cell death can therefore confer treatment resistance. A variety of genetic and epigenetic events as well as dysfunctional regulation of signaling networks have been identified as underlying causes of cell death resistance in childhood malignancies. Apoptosis pathways can be therapeutically exploited by enhancing proapoptotic signals or by neutralizing antiapoptotic programs. The challenge in the coming years will be to successfully transfer this knowledge into the development of innovative treatment approaches for children with cancer.
To search for novel strategies to enhance the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis pathways in glioblastoma, we used the B-cell lymphoma 2/Bcl2-like 2-inhibitor ABT-737. Here we report that ABT-737 and TRAIL cooperate to induce apoptosis in several glioblastoma cell lines in a highly synergistic manner (combination index <0.1). Interestingly, the concerted action of ABT-737 and TRAIL to trigger the accumulation of truncated Bid (tBid) at mitochondrial membranes is identified as a key underlying mechanism. ABT-737 and TRAIL cooperate to cleave BH3-interacting domain death agonist (Bid) into its active fragment tBid, leading to increased accumulation of tBid at mitochondrial membranes. Coinciding with tBid accumulation, the activation of Bcl2-associated X protein (Bax), loss of mitochondrial membrane potential, release of cytochrome-c and second mitochondria-derived activator of caspase (Smac) into the cytosol and caspase activation are strongly increased in cotreated cells. Of note, knockdown of Bid significantly decreases ABT-737- and TRAIL-mediated Bax activation and apoptosis. Also, caspase-3 silencing reduces ABT-737- and TRAIL-induced Bid cleavage and apoptosis, indicating that a caspase-3-driven, mitochondrial feedback loop contributes to Bid processing. Importantly, ABT-737 profoundly enhances TRAIL-triggered apoptosis in primary cultured glioblastoma cells derived from tumor material, underlining the clinical relevance. Also, ABT-737 acts in concert with TRAIL to suppress tumor growth in an in vivo glioblastoma model. In conclusion, the rational combination of ABT-737 and TRAIL cooperates to trigger tBid mitochondrial accumulation and apoptosis. This approach presents a promising strategy for targeting the apoptosis pathways in glioblastoma, which warrants further investigation.
Signaling via the intrinsic (mitochondrial) pathway of apoptosis represents one of the critical signal transduction cascades that control the regulation of cell death. This pathway is typically altered in human cancers, thereby providing a suitable target for therapeutic intervention. Members of the Bcl-2 family of proteins as well as cell survival signaling cascades such as the PI3K/Akt/mTOR pathway are involved in the regulation of mitochondria-mediated apoptosis. Therefore, further insights into the molecular mechanisms that form the basis for the control of mitochondria-mediated apoptosis will likely open new perspectives to bypass evasion of apoptosis and treatment resistance in human cancers.
Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications
(2012)
Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes. What was once regarded as a mere signal for protein degradation has turned out to be a major regulator of molecular signalling networks. Deregulation of ubiquitin signalling is closely associated with various human pathologies. Here, we summarize the current knowledge of ubiquitin signalling in immune deficiencies and cancer as well as the available therapeutic strategies targeting the ubiquitin system in combating these pathogenic conditions.
EFP1 is an ER stress-induced glycoprotein which interacts with the pro-apoptotic protein Par-4
(2009)
We have isolated the rat ortholog of EFP1 (EF-hand binding protein 1) as a novel interaction partner of the pro-apoptotic protein Par-4 (prostate apoptosis response-4). Rat EFP1 contains two thioredoxin domains, the COOH-terminal one harboring a CGFC motif, and has a similar protein domain structure as members of the protein disulfide isomerase (PDI) family. In REF52.2 and CHO cells, EFP1 colocalized with the endoplasmic reticulum (ER) marker PDI. Furthermore, EFP1 possesses catalytic activity as demonstrated by an insulin disulfide reduction assay. Western blot analysis revealed two EFP1 protein bands of approximately 136 and 155 kDa, representing different glycosylation states of the protein. Complex formation between EFP1 and Par-4 was confirmed in vitro and in vivo by co-immunoprecipitation, dot blot overlay and pull-down experiments. In CHO cells, coexpression of EFP1 and Par-4 resulted in enhanced Par-4-mediated apoptosis, which required the catalytic activity of EFP1. Interestingly, EFP1 was specifically upregulated in NIH3T3 cells after induction of ER stress by thapsigargin, tunicamycin, and brefeldin A, but not by agents that induce oxidative stress or ER-independent apoptosis. Furthermore, we could show that the induction of apoptosis by Ca2+ stress-inducing agents was significantly decreased after siRNA oligonucleotide-mediated knockdown of Par-4. Our data suggest that EFP1 might represent a cell-protective enzyme that could play an important role in the decision between survival and initiation of Par-4-mediated apoptosis.
Betulinic acid is a natural product with a range of biological effects, for example potent antitumor activity. This anticancer property is linked to its ability to induce apoptotic cell death in cancer cells by triggering the mitochondrial pathway of apoptosis. In contrast to the cytotoxicity of betulinic acid against a variety of cancer types, normal cells and tissue are relatively resistant to betulinic acid, pointing to a therapeutic window. Compounds that exert a direct action on mitochondria present promising experimental cancer therapeutics, since they may trigger cell death under circumstances in which standard chemotherapeutics fail. Thus, mitochondrion-targeted agents such as betulinic acid hold great promise as a novel therapeutic strategy in the treatment of human cancers.
Keywords: apoptosis, cancer, betulinic acid, mitochondria
Keywords: AIF, apoptosis inducing factor; Apaf-1, Apoptotic protease activating factor-1; BA, betulinic acid; DIABLO, direct IAP Binding protein with Low PI; HtrA2, high temperature requirement protein A; IAPs, Inhibitor of Apoptosis Proteins; MOMP, mitochondrial outer membrane permeabilization; ROS, reactive oxygen species; PARP, Poly (ADP-ribose) Polymerase; Smac, second mitochondria-derived activator of caspase; TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; zVAD.fmk, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
The ability to escape apoptosis or programmed cell death is a hallmark of human cancers, for example pancreatic cancer. This can promote tumorigenesis, since too little cell death by apoptosis disturbs tissue homeostasis. Additionally, defective apoptosis signaling is the underlying cause of failure to respond to current treatment approaches, since therapy-mediated antitumor activity requires the intactness of apoptosis signaling pathways in cancer cells. Thus, the elucidation of defects in the regulation of apoptosis in pancreatic carcinoma can result in the identification of novel targets for therapeutic interference and for exploitation for cancer drug discovery. Keywords: apoptosis; pancreatic cancer; TRAIL; IAPs; mitochondria
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
(2011)
The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing over the last years. A recent study identifies a new mechanism of action for the synergism of TRAIL and Bortezomib.
Leukotrienes constitute a group of bioactive lipids generated by the 5-lipoxygenase (5-LO) pathway. An increasing body of evidence supports an acute role for 5-LO products already during the earliest stages of pancreatic, prostate, and colorectal carcinogenesis. Several pieces of experimental data form the basis for this hypothesis and suggest a correlation between 5-LO expression and tumor cell viability. First, several independent studies documented an overexpression of 5-LO in primary tumor cells as well as in established cancer cell lines. Second, addition of 5-LO products to cultured tumor cells also led to increased cell proliferation and activation of anti-apoptotic signaling pathways. 5-LO antisense technology approaches demonstrated impaired tumor cell growth due to reduction of 5-LO expression. Lastly, pharmacological inhibition of 5-LO potently suppressed tumor cell growth by inducing cell cycle arrest and triggering cell death via the intrinsic apoptotic pathway. However, the documented strong cytotoxic off-target effects of 5-LO inhibitors, in combination with the relatively high concentrations of 5-LO products needed to achieve mitogenic effects in cell culture assays, raise concern over the assignment of the cause, and question the relationship between 5-LO products and tumorigenesis. Keywords: leukotriene, apoptosis, cell proliferation, mitogenic effects, cytotoxicity
Der ubiquitäre Redoxregulator Thioredoxin-1 (Trx-1) hat wichtige Funktionen für den zellulären Redoxstatus, Zellwachstum und Apoptose. Reaktive Sauerstoffspezies (ROS) sind beteiligt an der Pathogenese kardiovaskulärer Erkrankungen wie der Atherosklerose und werden zunehmend in ihrer Rolle als intra- und extrazelluläre Signalmoleküle charakterisiert. Ein Ungleichgewicht zwischen der Entstehung von ROS und ihrem Abbau durch antioxidative Systeme führt zu oxidativem Stress, zur Oxidation von Proteinen und letztlich zum Zelltod. Daher wurde in dieser Doktorarbeit untersucht, wie reaktive Sauerstoffspezies Trx-1 in Endothelzellen regulieren, welchen Einfluss dies für die Endothelzellapoptose hat und welche Bedeutung Antioxidantien, Stickstoffmonoxid (NO) und Schubspannung haben. In dieser Arbeit wurde gezeigt, dass H2O2 konzentrationsabhängig die Expression von Trx-1 beeinflusst. Geringe Konzentrationen H2O2 wie 10 und 50 µM induzierten Trx-1-mRNA nach 3 Stunden. Auf Proteinebene fand sich dann nach 6 Stunden eine transiente Hochregulation von Trx-1. Diese geringen Konzentrationen von H2O2 wirkten antiapoptotisch. Dieser antiapoptotische Effekt war von der Trx-1 Proteinexpression abhängig. Im Gegensatz dazu kam es bei hohen Konzentrationen H2O2 zu einer Degradierung von Trx-1. Durch das Antioxidans NAC und NO konnte der Abbau von Trx-1 unter höheren H2O2-Konzentrationen verhindert werden. Untersuchungen zum Mechanismus des Degradierungsprozesses ergaben, dass Trx-1 durch die Aspartatprotease Cathepsin D abgebaut wird. Der protektive Effekt von NO auf die Trx-1 Expression konnte auch im Gewebe eNOS-defizienter Mäuse gezeigt werden, da bereits eNOS-defiziente Mäuse in den Nieren weniger Trx-1 Protein aufwiesen im Vergleich zu Wildtyp-Kontrollmäusen. Bei der Entstehung endothelialer Läsionen und der Stabilität atheromatöser Plaques spielt die Endothelzellapoptose vermutlich eine wichtige Rolle. Trx-1 schützt Endothelzellen vor Apoptose, wird jedoch unter oxidativem Stress abgebaut. Faktoren, die Trx-1 unter oxidativem Stress stabilisieren wie NAC und NO, kommt daher eine besondere Bedeutung für die Endothelzellhomöostase zu.
Atherosklerotische Stenosen der Karotiden sind eine häufige Erkrankung mit variablem Verlauf und stellen durch ihre potentielle Emboligenität einen wichtigen Risikofaktor für zerebrale Ischämien dar. Klinische und paraklinische Parameter helfen, das individuelle Schlaganfallrisiko bei Patienten mit hochgradigen ACI-Stenosen einzuschätzen, das unmittelbar nach einem thrombembolischen Ereignis besonders hoch ist. Als histomorphologisches Korrelat dieser "Vulnerabilität" wird die Ruptur der fibrotischen Deckplatte der Plaque propagiert, die häufiger bei symptomatischen Patienten nachzuweisen ist. Sie korreliert mit der Infiltration der Gefäßwand durch aktivierte Leukozyten, die über molekulare und zelluläre Interaktionen die Zell- und Bindegewebskomposition der Plaque verändern können. Die strukturelle Integrität atherosklerotischer Läsionen beruht auf der extrazellulären Vernetzung von kollagenem Bindegewebe, das überwiegend von phänotypisch veränderten glatten Gefäßmuskelzellen produziert wird. Eine Hypothese besagt, dass die im Rahmen der Inflammation stattfindende Zunahme proapoptotischer Mediatoren über eine Ausdünnung der zellulären und bindegewebigen Strukturen zu einem Verlust an mechanischer Stabilität führt und somit eine symptomatische Ruptur begünstigt. Da der Nachweis einer Ruptur mit Exponierung des thrombogenen nekrotischen Kerns allerdings nur in einem Teil der symptomatischen Plaques und umgekehrt auch in einem Teil der asymptomatischen nachgewiesen werden kann, ist aber bislang unklar, ob o.g. Abläufe in der humanen Karotis-Atherosklerose tatsächlich mit einer klinischen Relevanz einhergehen. In der vorliegenden Arbeit wurde daher das Auftreten der Apoptose von glatten Gefäßmuskelzellen (mittels DNA in situ end labeling Technik, TUNEL-Färbung) in 38 prospektiv gesammelten Endarterektomie-Präparaten hochgradiger Karotisstenosen quantitativ erfasst und statistisch in Beziehung gesetzt zu Parametern der Plaque-Instabilität, klinisch definiert durch kürzliche (< 60 Tage zurückliegende) ischämische Ereignisse (n=19) und histopathologisch definiert über den Nachweis einer Plaque-Ruptur (n=14). Außerdem wurde eine morphometrische Analyse der einzelnen Plaque-Komponenten durchgeführt und deren Ergebnisse zu den zellulären und klinischen Parametern in Beziehung gesetzt. Die Morphometrie ergab keine signifikanten Unterschiede zwischen symptomatischen vs. asymptomatischen und rupturierten vs. unrupturierten Plaques was die Größe der fibrotischen Deckplatte, die durchschnittliche Dicke (Kern-Lumen-Distanz) und die dünnsten bzw. dicksten Stellen der Deckplatte anbelangt. Anzahl und Konzentration apoptotischer glatter Muskelzellen war deutlich (p<0,001) erhöht in symptomatischen, klinisch instabilen, Karotisplaques. Allerdings waren die Apoptose-Raten in Präparaten, die eine Plaque-Ruptur aufwiesen, nicht signifikant erhöht. Darüber hinaus fand sich kein Hinweis darauf, dass erhöhte Apoptose-Raten zu einem quantifizierbaren Verlust glatter Gefäßmuskelzellen in der fibrotischen Deckplatte führen. Auf dem Boden dieser Ergebnisse kann gefolgert werden, dass erhöhten Apoptose-Raten glatter Gefäßmuskelzellen in der humanen Atherosklerose offenbar eine tragende Bedeutung bei der Entwicklung thrombembolischer Ereignisse zukommt. Allerdings wird die Annahme, dass erhöhte Apoptose-Raten über einen Verlust an glatten Gefäßmuskelzellen Einfluss auf die morphometrischen Eigenschaften der fibrotischen Deckplatte atherosklerotischer Karotis-Läsionen nehmen und zu deren Ausdünnung führen durch die vorliegende Untersuchung nicht gestützt. Vielmehr scheint es plausibel, dass die Apoptose glatter Muskelzellen im Rahmen inflammatorischer Prozesse Einfluss auf die Komposition der Karotisplaque nimmt und so über eine Desintegration der zellulären und bindegewebigen Bestandteile zu reduzierter mechanischer Widerstandskraft und Rupturneigung führt.
Die Bedeutung der Apoptose und die zugrundeliegenden Mechanismen in verschiedenen pathophysiologischen Zuständen des Herzens sind noch weitgehend ungeklärt und es bleibt zu zeigen, daß die Apoptose-Signaltransduktion ähnlich reguliert wird, wie aus in vitro-Versuchen bekannt ist. Deshalb wurde die Apoptose in verschiedenen Tiermodellen kardialer Erkrankungen untersucht werden, um Hinweise auf die zugrundeliegende Signal-transduktion, durch Analyse der Proteine Bcl-2 und Bax, der finalen Exekutor-Caspase Caspase-3 oder p53 zu bekommen. Apoptose in der durch Hyperlipidämie induzierten Atherosklerose: In Aorten von 'Froxfield Heritable Hypercholesterolemic'-Kaninchen (genetische Hyperlipidämie) korrelierte die Apoptose von vaskulären glatten Muskelzellen und Makrophagen in fortgeschrittenen fibrösen Plaques mit einem 18-fachen Anstieg des proapoptotischen Bax. In Aorten Cholesterin gefütterter 'New Zealand White'-Kaninchen (0,25% Cholest., 12 Wochen) konnte eine erhöhte Baxexpression in Endothelzellen nachgewiesen werden, ohne daß morphologische Veränderungen zu beobachten waren. Die Apoptose in akut abgestoßenen allogenen Herztransplantaten (Rattenmodell) war von einer erhöhten Bax-Expression und einer totalen, posttranslationalen Degradation des antiapoptotischen Bcl-2 in ein spezifisches Degradationsprodukt durch eine Serinprotease gekennzeichnet. Die Rolle des wichtigen kardiovaskulären Mediators Stickstoffmonoxid (NO) auf die Apoptose wird kontrovers diskutiert. Da in der Zellkultur protektive Effekte von NO gezeigt werden konnten, wurde deren physiologische Relevanz in der durch Ischämie/Reperfusion induzierten Apoptose ex vivo im Langendorff-Rattenherzen untersucht. Es konnte gezeigt werden, daß Hemmung der endogenen NO-Synthese mit L-NG-Monomethyl-L-Arginin (LNMMA, 1mM) die Apoptose potenzierte und mit einer Aktivierung der Caspase-3 korrelierte. Bcl-2 und Bax wurden nicht reguliert. Untersuchung der Regulation der Proteinexpression der eNOS (endotheliale NO-Synthase) durch den proinflammatorischen/ proatherogenen Tumor-Nekrose-Faktor-[Alpha] (TNF[Alpha]) in der Endothelzellkultur (HUVEC) gaben Hinweise auf einen, die eNOS schützenden, Interaktionspartner. Zusammenfassend konnte in allen untersuchten Modellen für Herz(-Kreislauf)-Krankheiten Apoptose nachgewiesen werden, die jeweils spezifische Charakteristika zeigt, deren genauere Aufklärung interessante Ziele zukünftiger präventiver und therapeutischer Maßnahmen verspricht. Die Befunde weisen zudem auf antiapoptotische Effekte von NO - insbesondere durch die endotheliale NO-Synthaseaktivität - hin, deren genauere Charakterisierung dazu beitragen könnte, pathophysiologische Zustände der kardiovaskulären Biologie zu erklären.